05 feb: PANDORA LEVERER PÅ DE FINANSIELLE FORVENTNINGER OG PÅBEGYNDER TO-..
05 feb: Årsrapport 2018
05-02-2019 02:40:20

Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018

Financial report for the period 1 January to 31 December 2018

Lundbeck realized 8% growth in revenue (local currencies)

 and 48% growth in EPS in 2018

HIGHLIGHTS

  • Revenue reached DKK 18,117 million in 2018 representing an increase of 5% (8% in local currencies) compared to 2017
    • Revenue of Abilify Maintena® increased 20% to DKK 1,595 million (23% in local currencies)
    • Revenue of Brintellix®/Trintellix® increased 31% to DKK 2,182 million (37% in local currencies)
    • Revenue of Northera® increased 10% to DKK 1,806 million (15% in local currency)
    • Revenue of Onfi® increased 5% to DKK 3,165 million (12% in local currency)
    • Revenue of Rexulti® increased 38% to DKK 1,723 million (44% in local currencies)
    • Revenue in North America increased 1% to DKK 10,743 million (6% in local currencies)
    • Revenue in International Markets increased 3% to DKK 3,500 million (10% in local currencies)
    • Revenue in Europe increased 6% to DKK 2,970 million (6% in local currencies)
  • EBIT increased 20% to DKK 5,301 million in 2018 compared to DKK 4,408 million in 2017 and the EBIT margin reached 29.3% compared to 25.6% the year before
  • EPS grew 48% to DKK 19.66 in the period compared to DKK 13.28 the year before
  • Free cash flow reached DKK 3,074 million representing an increase of 39%, and the net cash position improved to DKK 6,635 million compared to DKK 3,677 million the year before
  • Lundbeck and Otsuka received positive headline results from a proof of concept study investigating the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder
  • For 2019, Lundbeck expects revenue to reach DKK 16.1–16.7 billion and EBIT to reach DKK 4.2–4.6 billion
  • The Board of Directors proposes to pay a dividend of DKK 12.00 per share, equal to a pay-out ratio of 61%
  • Lundbeck’s revised strategy, Expand and Invest to Grow, envisions expanded operating space in brain diseases, rebuilding the R&D pipeline through external innovation while maintaining focus on profitability aspiring to an EBIT-margin of at least 25%
  • Following Expand and Invest to Grow, Lundbeck will see increased capital needs related to our strategic initiatives and therefore, revises the dividend policy from the current range of 60-80% of net profit to a range of 30-60% of net profit from 2019 onwards

In connection with the financial report, Lundbeck’s President and CEO Deborah Dunsire said:

“Lundbeck has delivered its best financial result ever and has more than achieved the financial targets set in 2016. Our goal now is to achieve sustainable, profitable growth through maximizing our neuroscience platform and strengthening our pipeline across all phases. We have conducted a strategic review and some of the elements include broadening the disease focus within brain health, as well as accelerating our internal pipeline and accessing external innovation to capitalize on our competitive edge”.

DKK million

FY 2018

FY 2017

Growth

Reported Revenue

18,117

17,234

5%

Reported EBIT

5,301

4,408

20%

Reported EPS

19.66

13.28

48%

Reported EBIT margin

29.3%

25.6%

-

 

 

 

 

Core Revenue*

18,117

17,234

5%

Core EBIT*

6,158

5,115

20%

Core EPS*

23.71

16.50

44%

Core EBIT margin*

34.0%

29.7%

-

       *For definition of the measures “Core Revenue”, “Core EBIT” and “Core EPS”, see note 4 Core reporting

Attachment

logo.jpg

Relateret indhold
12 jul - 
USA: Trump trækker forslag om ændring af medicinrabatte..
11 jul - 
Aktier/åbning: Generelt positive toner og lille kursrea..
09 jul - 
Tirsdagens aktier: Langt mellem plusser - Danske Bank s..
Relateret debat
10 jul - 
Det er hver gang Trump er ude at sige at medicinen skal..
09 jul - 
Sker der ikke snart positivt i lundbeck? Aktien siver o..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktier/tendens: Ørsted tiltænkt helterolle i positiv aktieåbning

19-07-2019 08:09:28
Der er positive nyheder fra både den danske energikoncern Ørsted og biotekselskabet Genmab som oplæg til fredagens danske aktiehandel, hvor markedet før åbningen generelt er bagud i forhold til den stigning de amerikanske aktier præsterede i torsdagens handel.Sammen med stigende futures for både det amerikanske S&P 500-indeks og for det tyske DAX-indeks tidlig fredag morgen peger det mod en positi..

Danske Bank Q2: Kundeflugten fortsætter i udfordret bank

18-07-2019 11:06:22
Kunder siger fortsat farvel til Danske Bank - omend i et langsommere tempo end tidligere. I andet kvartal valgte 4300 Nemkonto-kunder at slukke for den forbindelse til banken, hvor de første seks måneder samlet gav en kundeafgang på 13.600 Nemkonto-kunder svarende til 1 pct. af bankens Nemkonto-kundebase.Det er fortsat bankens hvidvasksag i Estland, der danner ringe i vandet - men også sagen om pr..

Aktier/tendens: Storbanker i fokus efter årle morgen-regnskaber

18-07-2019 08:26:01
Det er storbankerne Nordea og Danske Bank, der tager overskrifterne på det danske aktiemarked torsdag morgen og lægger retningen for børsens C25-indeks, der samtidig vil være presset af internationale kursfald.I USA lukkede Wall Street med fald i størrelsesordenen 0,4-0,7 pct., og i futuresmarkedet er faldene blevet uddybet med yderligere 0,3-0,5 pct.I Asien har investorernes mangel på begejstring..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Lundbeck A/S 251,80 -2,9% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. juli 2019 08:33:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB2 - 2019-07-21 08:33:09 - 2019-07-21 08:33:09 - 1 - Website: OKAY